AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alfa?

Abstract Interferon alfa (IFNα) was one of the first agents to be used therapeutically in AIDS-associated Kaposi's sarcoma (KS) more than 25 years ago, and induces tumor regression in a subset of patients. Although much has been learned about the clinical role of IFNα in KS treatment, little is...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine & growth factor reviews 2007-10, Vol.18 (5), p.395-402
Main Author: Krown, Susan E
Format: Article
Language:English
Subjects:
Advanced Basic Science
AIDS-Related Opportunistic Infections - drug therapy
AIDS-Related Opportunistic Infections - etiology
Animals
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Humans
Interferon
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Kaposi's sarcoma
Sarcoma, Kaposi - drug therapy
Sarcoma, Kaposi - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Interferon alfa (IFNα) was one of the first agents to be used therapeutically in AIDS-associated Kaposi's sarcoma (KS) more than 25 years ago, and induces tumor regression in a subset of patients. Although much has been learned about the clinical role of IFNα in KS treatment, little is currently known about the mechanism(s) by which IFNα causes KS regression. This is despite a growing understanding of both KS pathogenesis and relevant IFNα activities. To a large extent other agents have supplanted IFNα as treatments for KS, but there may still remain a therapeutic role for IFNα, possibly in combination with other agents targeting angiogenesis and/or HHV-8-encoded human gene homologs that encode proteins involved in cell cycle regulation and signaling.
ISSN:1359-6101
DOI:10.1016/j.cytogfr.2007.06.005